About: Karen H. Antman

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Karen H. Antman Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

Dean of Boston University School of Medicine

Attributes	Values
rdf:type	Item
description	Forscher (de) ikertzailea (eu) 연구원 (ko) ricercatore (it) 研究者 (ja) investigador (es) chercheur (fr) wetenschapper (nl) дослідниця (uk) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh) Dean of Boston University School of Medicine (en)
rdfs:label	K Antman (es) Karen H. Antman (en) Karen H. Antman (nl) Karen H. Antman (ast)
skos:prefLabel	K Antman (es) Karen H. Antman (en) Karen H. Antman (nl) Karen H. Antman (ast)
name	K Antman (es) Karen H. Antman (en) Karen H. Antman (nl) Karen H. Antman (ast)
Freebase ID	wds:Q6369669-3B8D3798-DA7A-4BC0-9154-E20058C66015
Freebase ID	/m/0g5p_jy
given name	wds:Q6369669-BAF64AD9-041A-4F76-BD88-C99CA9D5AA99
given name	Karen
image	wds:Q6369669-280103A8-9EC4-4013-AAEB-9D2C8204651F
instance of	wds:Q6369669-44400516-B962-405E-B737-BA8A9457F337
image
instance of	Homo sapiens
skos:altLabel	K Antman (en) K Antman (nl) K Antman (ast) Karen Antman (en)
occupation	wds:Q6369669-B829D325-3725-4729-9637-93672C44EBBB
employer	wds:Q6369669-6FC4A2B5-7004-43A4-B20D-B7DEC1EC1E95
NUKAT ID	wds:Q6369669-573185C1-D44E-4F86-82C9-624877411C14
sex or gender	wds:Q6369669-A806B196-7CFE-4E0D-B254-8F7AE40EB74F
ISNI	wds:Q6369669-75E7EAD7-1E2F-4CD4-95AE-16CFB4D7CC87
VIAF ID	wds:Q6369669-C15D709C-3B19-472B-A076-801F3DC243CE
IdRef ID	wds:Q6369669-D8012B7C-A27D-4372-83B3-5EA3572E151E
family name	wds:Q6369669-50579482-5183-47C2-9F20-C1476D5CBECB
National Library of Israel J9U ID	wds:Q6369669-93409D59-9E81-40C7-A302-97E05919D2E1
VIAF ID	http://viaf.org/viaf/26061396
IdRef ID	http://www.idref.fr/122287835/id
occupation	researcher
employer	Boston University School of Medicine
NUKAT ID	n2007102173
sex or gender	female organism
ISNI	0000000117526015
VIAF ID	26061396
IdRef ID	122287835
family name	Antman
National Library of Israel J9U ID	987007364837805171
ORCID iD	wds:Q6369669-A0295714-4A74-445F-BC82-648F7596F567
ORCID iD	https://orcid.org/0000-0002-1093-8356
ORCID iD	0000-0002-1093-8356
is owl:sameAs of	Karen H. Antman
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q6369669 Karen H. Antman
is author of	A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support Update on malignant mesothelioma. Clinical staging and the tendency of malignant pleural mesotheliomas to remain localized Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. New biology and therapies in soft tissue sarcomas. Introduction: the history of arsenic trioxide in cancer therapy. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas Specific barriers to the conduct of randomized trials. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes Multimodality therapy in the management of angiosarcoma of the breast High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry Complementary and alternative medicine: the role of the cancer center A phase II Southwest Oncology Group study of cisplatin and continuous infusion vinblastine in the treatment of advanced soft tissue sarcoma Chromosome changes in malignant mesothelioma Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide Microangiopathic hemolytic anemia and cancer: a review Kaposi's Sarcoma Mesothelioma following Wilms' tumor in childhood Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response Malignant mesothelioma following treatment for Hodgkin's disease. Malignant mesothelioma following radiation exposure The crisis in clinical cancer research. Third-party insurance and investigational therapy. Chemotherapy for malignant mesothelioma The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software